M
426.04
-5.96 (-1.38%)
| Previous Close | 432.00 |
| Open | 430.23 |
| Volume | 35,487 |
| Avg. Volume (3M) | 347,383 |
| Market Cap | 9,675,973,632 |
| Price / Earnings (Forward) | 666.67 |
| Price / Sales | 10.33 |
| Price / Book | 16.79 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2026 |
| Profit Margin | -123.38% |
| Operating Margin (TTM) | -57.79% |
| Diluted EPS (TTM) | -17.83 |
| Total Debt/Equity (MRQ) | 16.85% |
| Current Ratio (MRQ) | 5.91 |
| Operating Cash Flow (TTM) | -395.31 M |
| Levered Free Cash Flow (TTM) | -274.11 M |
| Return on Assets (TTM) | -25.56% |
| Return on Equity (TTM) | -50.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Madrigal Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.3
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | 1.25 |
|
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 7.73% |
| % Held by Institutions | 108.28% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 964.00 (Barclays, 126.27%) | Buy |
| Median | 745.00 (74.87%) | |
| Low | 529.00 (B of A Securities, 24.17%) | Hold |
| Average | 746.00 (75.10%) | |
| Total | 2 Buy, 1 Hold | |
| Avg. Price @ Call | 478.83 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 20 Feb 2026 | 529.00 (24.17%) | Hold | 435.01 |
| Barclays | 28 Jan 2026 | 964.00 (126.27%) | Buy | 496.54 |
| Citizens | 20 Jan 2026 | 745.00 (74.87%) | Buy | 504.95 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 02 Feb 2026 | Announcement | Madrigal Pharmaceuticals to Release Fourth-Quarter and Full-Year 2025 Financial Results and Host Webcast on February 19, 2026 |
| 22 Jan 2026 | Announcement | Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) |
| 21 Jan 2026 | Announcement | Madrigal Pharmaceuticals Announces Grant of Inducement Award under Nasdaq Listing Rule 5635(c)(4) |
| 09 Jan 2026 | Announcement | Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor |
| 02 Jan 2026 | Announcement | Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |